Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 4/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015446 | 1.00 | KCNH2 (0.40) | KCNH2L3MBTL1HSD17B1MAOBMAPT | |
| SCHEMBL5017288 | 0.86 | HSD17B1 (0.40) | KCNH2L3MBTL1HSD17B1MAOBMAPT | |
| SCHEMBL5017289 | 0.86 | HSD17B1 (0.40) | KCNH2L3MBTL1HSD17B1MAOBMAPT | |
| SCHEMBL27566193 | 0.84 | HSD17B1 (0.43) | KCNH2L3MBTL1HSD17B1MAOBMAPT | |
| SCHEMBL14086510 | 0.84 | MAPT (0.39) | KCNH2L3MBTL1HSD17B1MAOBMAPT | |
| SCHEMBL6030409 | 0.77 | L3MBTL1 (0.62) | KCNH2L3MBTL1MAPTNAMPTGRIN2B | |
| SCHEMBL5025532 | 0.77 | KDR (0.45) | KCNH2L3MBTL1MAOBMAPTMKNK2 | |
| SCHEMBL19662826 | 0.76 | MKNK1 (0.61) | HSD17B1MAPTSMN1; SMN2NAMPTMKNK1 | |
| SCHEMBL2952564 | 0.75 | L3MBTL1 (0.57) | L3MBTL1MAPTSMN1; SMN2NAMPT | |
| SCHEMBL7331946 | 0.74 | L3MBTL1 (0.56) | L3MBTL1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | KCNH2 991/4885L3MBTL1 166/4885HSD17B1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.